Warner-Lambert whistleblower
Executive Summary
A former employee of Warner-Lambert has brought suit under the Federal False Claims Act "based on certain alleged sales and marketing practices concerning...Neurontin and Accupril," Warner-Lambert discloses in May 10 SEC filing. The Boston U.S. Attorney's office is conducting an investigation of potential off-label promotions of Neurontin (1"The Pink Sheet" April 3, p. 3)